Latest Period
Q4 2025
- Info
- Insider Trading
- Financials
- Holders
Security Snapshot
SOLENO THERAPEUTICS INC - Common Stock (SLNO) Institutional Ownership
CUSIP: 834203309
13F Institutional Holders and Ownership History from Q3 2022 to Q1 2026
Institutions Reporting
245
Shares (Excl. Options)
64,847,444
Price
$46.30
Save this security page for your next review
Keep this CUSIP in your watchlists so you can revisit quarter changes from one place.
- Type / Class
- Equity / Common Stock
- Symbol
- SLNO on Nasdaq
- Shares outstanding
- 53,569,806
- Price per share
- $33.48
- All holders as of 31 Dec 2025
- Q4 2025
- Total 13F shares
- 64,847,444
- Total reported value
- $3,002,897,757
- % of total 13F portfolios
- 0.01%
- Share change
- -962,474
- Value change
- -$196,506,339
- Number of holders
- 245
- Price from insider filings
- $33.48
Reported Shares, Excluding Options vs Price
Reported Value, Excluding Options
Total Investors
Quick Takeaways
- SLNO - SOLENO THERAPEUTICS INC - Common Stock is tracked under CUSIP 834203309.
- 245 institutions reported positions in Q4 2025.
- 10 significant owners is listed from Schedule 13D/13G reporting.
What Changed
- Holder count moved from 245 to 9 between Q4 2025 and Q1 2026.
- Reported value moved from $3,002,897,757 to $1,764,724.
Why This Matters
- You can quickly see who holds this security, then open quarter and manager detail pages for full evidence.
- 13F and Schedule 13D/13G sections are kept together so you can cross-check institutional and beneficial ownership context.
Source Evidence
Source: SEC Form 13F
Open SEC Evidence
Latest holder context comes from 245 institutions filings for Q4 2025.
Investment Quick Answers
What is CUSIP 834203309?
CUSIP 834203309 identifies SLNO - SOLENO THERAPEUTICS INC - Common Stock in SEC 13F datasets.
Where can I see the latest institutional holders?
Review the Q4 2025 holders report and the ownership history table below.
Continue With The Right Next Step
- Latest 13F filings - identify new institutional portfolio moves.
- Latest Schedule 13D/13G reports - cross-check beneficial ownership events.
- All institutional ownership pages - compare nearby CUSIPs and holder concentration.
Recent Quarterly Holder Reports
Open recent reporting periods for CUSIP 834203309:
Significant Owners of SOLENO THERAPEUTICS INC - Common Stock (SLNO) based on Schedule 13D/G filings
| Filer | Ownership | Change % | Holdings Value | Net Change | Nb Shares | Change % | Reporting Name | Report Period |
|---|---|---|---|---|---|---|---|---|
| FMR LLC | 15% | +120% | $678,796,830 | +$389,571,468 | 7,833,778 | +135% | FMR LLC | 31 Jul 2025 |
| JANUS HENDERSON GROUP PLC | 13% | +18% | $297,973,475 | +$46,574,843 | 7,178,354 | +19% | JANUS HENDERSON GROUP PLC | 31 Dec 2025 |
| PRICE T ROWE ASSOCIATES INC /MD/ | 6.9% | +34% | $299,939,842 | +$91,911,561 | 3,461,510 | +44% | T. Rowe Price Associates, Inc. | 30 Jun 2025 |
| WELLINGTON MANAGEMENT GROUP LLP | 6.2% | $137,929,386 | 3,322,799 | Wellington Management Group LLP | 31 Dec 2025 | |||
| Avoro Capital Advisors LLC | 5.4% | +32% | $120,379,000 | +$35,283,500 | 2,900,000 | +41% | Avoro Capital Advisors LLC | 31 Dec 2025 |
| ADAGE CAPITAL PARTNERS GP, L.L.C. | 6.4% | $204,422,873 | 2,775,976 | Adage Capital Management, L.P. | 31 Dec 2024 | |||
| BlackRock, Inc. | 5.5% | +16% | $231,754,330 | +$63,374,124 | 2,766,225 | +38% | BlackRock, Inc. | 30 Jun 2025 |
| Vivo Opportunity Fund Holdings, L.P. | 4.2% | -46% | $152,178,416 | -$115,402,258 | 2,251,160 | -43% | Vivo Opportunity Fund Holdings, L.P. | 30 Sep 2025 |
| Adage Capital Management, L.P. | 2.6% | -64% | $94,746,538 | -$146,988,629 | 1,401,576 | -61% | Adage Capital Management, L.P. | 30 Sep 2025 |
| Nantahala Capital Management, LLC | 2% | -60% | $86,766,978 | -$140,918,982 | 1,001,350 | -62% | Nantahala Capital Management, LLC | 30 Jun 2025 |
As of 31 Dec 2025, 245 institutional investors reported holding 64,847,444 shares of SOLENO THERAPEUTICS INC - Common Stock (SLNO). This represents 121% of the company’s total 53,569,806 outstanding shares.
Top 25 Institutional Shareholders
The largest institutional shareholders of SOLENO THERAPEUTICS INC - Common Stock (SLNO) together control 94% of the company’s outstanding shares — a level of ownership often associated with strong institutional conviction and long‑term capital commitment.
| Institution | Ownership % | Shares Held | Share Change % | Portfolio % | Holdings Value |
|---|---|---|---|---|---|
| FMR LLC | 15% | 8,079,304 | +1% | 0.02% | $374,071,758 |
| JANUS HENDERSON GROUP PLC | 13% | 7,178,354 | +19% | 0.15% | $332,302,144 |
| BlackRock, Inc. | 7.2% | 3,871,639 | +11% | 0% | $179,256,886 |
| WELLINGTON MANAGEMENT GROUP LLP | 6.2% | 3,322,799 | +44% | 0.03% | $153,845,595 |
| PRICE T ROWE ASSOCIATES INC /MD/ | 6.2% | 3,318,698 | -15% | 0.02% | $153,657,000 |
| VANGUARD GROUP INC | 5.7% | 3,060,361 | +9% | 0% | $141,694,714 |
| Avoro Capital Advisors LLC | 5.4% | 2,900,000 | +13% | 1.3% | $134,270,000 |
| STATE STREET CORP | 4.9% | 2,649,626 | +22% | 0% | $122,677,684 |
| Nantahala Capital Management, LLC | 2.5% | 1,314,002 | +52% | 3.6% | $60,838,293 |
| MILLENNIUM MANAGEMENT LLC | 2.3% | 1,236,321 | +26% | 0.04% | $57,241,662 |
| Commodore Capital LP | 2.2% | 1,200,000 | -11% | 3.7% | $55,560,000 |
| BRAIDWELL LP | 2.2% | 1,187,859 | -7.3% | 1.8% | $54,997,872 |
| GEODE CAPITAL MANAGEMENT, LLC | 2.2% | 1,163,338 | +7.2% | 0% | $53,870,660 |
| Polar Capital Holdings Plc | 2.1% | 1,136,929 | -4.5% | 0.24% | $52,639,813 |
| Woodline Partners LP | 2.1% | 1,111,778 | +311% | 0.2% | $51,475,321 |
| Deep Track Capital, LP | 1.9% | 1,000,000 | 1.1% | $46,300,000 | |
| GOLDMAN SACHS GROUP INC | 1.7% | 913,050 | +64% | 0.01% | $42,274,215 |
| Vivo Capital, LLC | 1.7% | 894,909 | -61% | 2.7% | $41,434,287 |
| Invesco Ltd. | 1.6% | 875,019 | -42% | 0.01% | $40,513,380 |
| READYSTATE ASSET MANAGEMENT LP | 1.6% | 874,447 | +325% | 1.8% | $40,486,896 |
| FRANKLIN RESOURCES INC | 1.5% | 823,958 | -1.4% | 0.01% | $38,149,268 |
| Pictet Asset Management Holding SA | 1.2% | 624,128 | +13% | 0.03% | $28,897,126 |
| Bank of New York Mellon Corp | 1.2% | 621,811 | -0.86% | 0.01% | $28,789,839 |
| Hood River Capital Management LLC | 1.2% | 618,005 | +0.75% | 0.31% | $28,613,632 |
| Artia Global Partners LP | 1% | 533,698 | -21% | 4% | $24,710,217 |
Institutional Holders of SOLENO THERAPEUTICS INC - Common Stock (SLNO) across Reporting Periods
| Period | Reported Shares, Excl. Options | Value, Excl. Options | Value Change | Price (Median) | Investors |
|---|---|---|---|---|---|
| 2026 Q1 | 52,698 | $1,764,724 | -$316,926 | $33.48 | 9 |
| 2025 Q4 | 64,847,444 | $3,002,897,757 | -$196,506,339 | $46.30 | 245 |
| 2025 Q3 | 65,165,847 | $4,403,391,909 | +$507,196,048 | $67.60 | 237 |
| 2025 Q2 | 56,749,470 | $4,754,316,405 | +$213,454,357 | $83.78 | 231 |
| 2025 Q1 | 54,568,286 | $3,901,554,193 | +$304,734,926 | $71.45 | 215 |
| 2024 Q4 | 51,039,620 | $2,293,782,533 | +$169,954,638 | $44.95 | 164 |
| 2024 Q3 | 47,119,847 | $2,378,750,710 | +$200,292,187 | $50.49 | 140 |
| 2024 Q2 | 43,315,547 | $1,767,618,917 | +$339,170,617 | $40.80 | 112 |
| 2024 Q1 | 34,986,278 | $1,496,099,214 | +$153,335,358 | $42.80 | 97 |
| 2023 Q4 | 31,409,972 | $1,264,282,488 | +$428,860,586 | $40.25 | 76 |
| 2023 Q3 | 20,301,195 | $598,794,549 | +$451,363,927 | $29.51 | 54 |
| 2023 Q2 | 4,852,710 | $20,757,863 | +$7,837,293 | $4.29 | 22 |
| 2023 Q1 | 3,071,637 | $6,538,076 | +$3,161,387 | $2.14 | 20 |
| 2022 Q4 | 2,785,956 | $5,517,109 | +$81,616 | $1.98 | 22 |
| 2022 Q3 | 2,781,988 | $4,645,586 | +$4,630,000 | $1.67 | 14 |